Destiny Pharma plc (JPJ:DEST), today announces it’s shares have been admitted to trade on JP Jenkins

Destiny Pharma plc (JPJ:DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening infections.

About Destiny Pharma:

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The Company’s drug development pipeline includes two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.

Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

To read the full announcement, please use this link.